{
    "clinical_study": {
        "@rank": "72291", 
        "acronym": "PROBELTEII", 
        "arm_group": [
            {
                "arm_group_label": "Antioxidant supplement", 
                "arm_group_type": "Experimental", 
                "description": "Treatment consist of consuming 65g of punicalagin and 3,3g of hydroxytyrosol (plus 331,7g of maltodextrin) three times daily, during 8 weeks."
            }, 
            {
                "arm_group_label": "Control supplement", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Treatment consist of consuming 400g of maltodextrin three times daily, during 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "A crossover trial was carried out in healthy volunteers aged 45-70 years and BMI <30 kg/m2.\n      Subjects consumed a Antioxidant Supplement (AS) containing 65 mg of punicalagin mixed with\n      3.3 mg of hydroxytyrosol 3 times daily or a Control Supplement (CS) with maltodextrin for an\n      8 wk each phase with 4-wk rest period. Supplementation order was randomly assigned and the\n      consumption of derivative products of punicalagin and/or hydroxytyrosol restricted. The\n      endothelial function parameters (brachial artery flow-mediated dilation (FMD), biochemical\n      markers), inflammatory markers and nutritional status were evaluated before and after each\n      phase. Previously a pilot study was completed with no placebo (n=30) to determinate the\n      effective dose of Functional Supplement."
        }, 
        "brief_title": "Punicalagin and Hydroxytyrosol Mixture on Different Inflammatory Markers", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "condition_browse": {
            "mesh_term": "Cardiovascular Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women from 45 to 75 years old;\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Individuals with cardiovascular risk factors on drug treatment (dyslipidemia,\n             hypertension, Diabetes Mellitus);\n\n          -  Individuals with Metabolic Syndrome;\n\n          -  Individuals with familiar background of premature cardiovascular disease;\n\n          -  Individuals with BMI \u2265 30 kg/m2;\n\n          -  Women that still maintain your menstrual cycle;\n\n          -  Individuals with increased alcohol consumption 30g/day;\n\n          -  Individuals that stop smoking in the next 20 weeks (during the study);\n\n          -  Individuals that consume antioxidant supplement, drugs, \u03c9-3 supplements, vitamins,\n             minerals, prebiotics or/and probiotics;\n\n          -  Women that consume oral contraceptive;\n\n          -  Individuals with mental disease or low cognitive function;\n\n          -  Individuals with severe diseases (hepatic, kidney, cancer\u2026);\n\n          -  Individuals with drugs or supplements consumption to weight lost;\n\n          -  Pregnant women or lactating;\n\n          -  Individuals with intensive physical activity;\n\n          -  Individuals with physical problems complying with the recommendations of physical\n             activity and diet general recommendations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02042742", 
            "org_study_id": "PROBELTEII"
        }, 
        "intervention": [
            {
                "arm_group_label": "Antioxidant supplement", 
                "description": "Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.", 
                "intervention_name": "punicalagin and hydroxytyrosol mixture", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Punicalagin and hydroxytyrosol"
            }, 
            {
                "arm_group_label": "Control supplement", 
                "description": "During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.", 
                "intervention_name": "Control supplement (maltodextrin)", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Maltodextrin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antioxidants", 
                "3,4-dihydroxyphenylethanol", 
                "Phenylethyl Alcohol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cross-over studies", 
            "Antioxidants", 
            "Hydroxytyrosol", 
            "Punicalagin", 
            "Treatment outcome", 
            "Inflammatory markers", 
            "Endothelial function", 
            "Humans", 
            "Adults", 
            "volunteers"
        ], 
        "lastchanged_date": "January 20, 2014", 
        "link": [
            {
                "description": "Institute for Health Research IdiPAZ", 
                "url": "http://www.idipaz.es"
            }, 
            {
                "description": "Research group in Nutrition and Functional Foods (NUTRINVEST)", 
                "url": "http://www.nutrinvest.com"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28061"
                }, 
                "name": "Hospital Universitario La Paz"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Punicalagin and Hydroxytyrosol Mixture on Different Inflammatory Markers Related With Cardiovascular Disease: a Crossover Study in Healthy Middle-aged Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Inflammatory markers (Fibrinogen, gelsolin, thrombospondin, interleukin 6 and PCR) will be measured at week 0 and 8 for phase I, and at week 12 and 20 for phase II", 
            "measure": "Change in the Inflammatory markers after 8 weeks treatment", 
            "safety_issue": "Yes", 
            "time_frame": "0, 8, 12 and 20 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02042742"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Parameters measured were: plasma antioxidant capacity (FRAP, ferric reducing antioxidant power) and lipidic peroxidation (TBARS, thiobarbituric acid reactive substances assay), oxidized LDL, paraoxonase 1, F2-isoprostanes. Will be measured at week 0 and 8 for phase I, and at week 12 and 20 for phase II.", 
                "measure": "Change in Oxidative Stress Parameters", 
                "safety_issue": "Yes", 
                "time_frame": "0, 8, 12 and 20 weeks"
            }, 
            {
                "description": "Parameters measured were: glucose, basal insulin, HbA1c (in diabetic patients), HOMA (homeostasis model assessment ) index (glycemic insulin sensitivity index was calculated using the formula: HOMA-IR ( (homeostasis model assessment  insulin resistance) = fasting glucose (mmol/l)/fasting immunoreactive insulin (mU/ml)/22\u20225).Will be measured at week 0 and 8 for phase I, and at week 12 and 20 for phase II", 
                "measure": "Change in Glucose Metabolism", 
                "safety_issue": "Yes", 
                "time_frame": "0, 8, 12 and 20 weeks"
            }, 
            {
                "description": "Parameters measured were: Cholesterol, LDL-Cholesterol, HDL-Cholesterol, Triglycerides. Will be measured at week 0 and 8 for phase I, and at week 12 and 20 for phase II", 
                "measure": "Change in Lipid profile", 
                "safety_issue": "No", 
                "time_frame": "0, 8, 12 and 20 weeks"
            }, 
            {
                "description": "Parameters measured were: Brachial artery flow-mediated dilation (FMD), blood pressure, eNOS, vascular endothelial cell adhesion molecule -1 and p-selectin. Will be measured at week 0 and 8 for phase I, and at week 12 and 20 for phase II", 
                "measure": "Change in Endothelial function", 
                "safety_issue": "Yes", 
                "time_frame": "0, 8, 12 and 20 weeks"
            }, 
            {
                "description": "Parameters measured were: Prothrombin time and activity, INR. Will be measured at week 0 and 8 for phase I, and at week 12 and 20 for phase II", 
                "measure": "Change in Coagulation markers", 
                "safety_issue": "No", 
                "time_frame": "0, 8, 12 and 20 weeks"
            }, 
            {
                "description": "Parameters measured were: Weight, Height and waist circumference, muscle mass percentage (MM%), fat mass percentage (FM%), free fat mass percentage(FM%). Will be measured at week 0 and 8 for phase I, and at week 12 and 20 for phase II", 
                "measure": "Change in Anthropometric and body composition parameters", 
                "safety_issue": "No", 
                "time_frame": "0, 8, 12 and 20 weeks"
            }, 
            {
                "description": "Parameters measured were: transaminases and creatinine. Will be evaluated during all the study visits", 
                "measure": "Adverse effects", 
                "safety_issue": "Yes", 
                "time_frame": "0 to 20 weeks"
            }, 
            {
                "description": "Parameters measured were: adherence and tolerance to the products. Will be evaluated during all study visits.", 
                "measure": "Adherence and Tolerance Parameters", 
                "safety_issue": "No", 
                "time_frame": "0 to 20 weeks"
            }
        ], 
        "source": "Instituto de Investigaci\u00f3n Hospital Universitario La Paz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto de Investigaci\u00f3n Hospital Universitario La Paz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}